October 18, 2023
BRANDTON, KS - Results from the landmark Phase 3 HYPERTrial have been published in the prestigious Journal of the American Medical Association (JAMA), further demonstrating the significant blood pressure lowering benefits of Brand X (fictusapril).
The randomized, double-blind, placebo-controlled trial enrolled over 1,500 patients with stage 1 or 2 hypertension.
Patients treated with once-daily Brand X achieved an average reduction in systolic blood pressure from baseline that was 12 mmHg greater than placebo after 12 weeks.
"The magnitude of effect and safety demonstrated in this rigorously conducted trial confirms the benefit Brand X can provide patients with high blood pressure warranting treatment," said lead author Dr. Linda Park.
Adverse events in the Brand X group occurred at low rates comparable to placebo, with dizziness, fatigue, and headaches being the most frequent.
“We are thrilled to have the HYPERTrial results published in such a well-respected journal, adding to the growing body of peer-reviewed evidence for Brand X,” said CEO of Pharma CO AG.
View the clinical study summary
To view the HYPERTrial clinical study summary, click here.